Nlrp3 (Nlr Family Pyrin Domain Containing 3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
{{#vardefine:wikiId|}}
| Protein Name | NLRP3 |
|---|
| Gene Symbol | NLRP3 |
|---|
| UniProt ID | Q9NPF4 |
|---|
| PDB Structures | 4KXF, 6N8P, 7AL0 |
|---|
| Molecular Weight | ~118 kDa |
|---|
| Subcellular Localization | Cytoplasm, inflammasome complex |
|---|
| Protein Family | NOD-like receptor family |
|---|
| Aliases | NLRP3, CIAS1, PYPAF1, NALP3, Cryopyrin |
|---|
NLRP3 (NLR Family Pyrin Domain Containing 3) is a pattern recognition receptor that forms the NLRP3 inflammasome, a multi-protein complex that activates caspase-1 and triggers the release of pro-inflammatory cytokines IL-1β and IL-18. The NLRP3 inflammasome is a central driver of neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
NLRP3 contains three functional domains:
- PYD (N-terminal): Pyrin domain for homotypic interactions with ASC
- NACHT: Central nucleotide-binding domain responsible for oligomerization and ATP hydrolysis
- LRR (C-terminal): Leucine-rich repeat domain for ligand sensing
The NLRP3 inflammasome complex includes:
- NLRP3 (sensor)
- ASC (adaptor, encoded by PYCARD)
- Pro-caspase-1 (effector)
In the healthy nervous system, NLRP3:
- Provides innate immune surveillance
- Responds to pathogen-associated molecular patterns (PAMPs)
- Initiates inflammatory responses to cellular stress
- Facilitates tissue repair
Under normal conditions, NLRP3 expression is low and tightly controlled by negative regulators.
NLRP3 contributes to AD pathogenesis through:
- Aβ-Induced Activation: Aβ oligomers and fibrils directly activate NLRP3 in microglia
- IL-1β Release: Chronic IL-1β release promotes tau pathology and synaptic loss
- Microglial Priming: NLRP3 activation enhances microglial phagocytic activity but also inflammatory burden
- Synaptic Pruning: Excessive IL-1β accelerates complement-mediated synapse elimination
- Blood-Brain Barrier Disruption: NLRP3 contributes to BBB dysfunction
In PD, NLRP3 mediates:
- α-Synuclein-Induced Inflammation: NLRP3 is activated by α-synuclein aggregates
- Dopaminergic Neuron Death: IL-1β and IL-18 contribute to nigral neuron loss
- Microglial Activation: Sustained neuroinflammation in substantia nigra
- Mitochondrial DNA Sensing: NLRP3 recognizes mitochondrial DAMPs
- Amyotrophic Lateral Sclerosis (ALS): NLRP3 activation in microglia and astrocytes
- Multiple Sclerosis: Contributes to demyelination and lesion progression
- Traumatic Brain Injury: Mediates post-traumatic neuroinflammation
- Huntington's Disease: NLRP3 activation exacerbates mutant huntingtin toxicity
NLRP3 inflammasome activation follows a two-step priming and activation model:
flowchart TD
subgraph Priming
A[TLR Activation<br/>LPS, Aβ, α-Syn] --> B[NF-κB Activation] -->
B --> C[NLRP3 Gene Transcription] -->
C --> D[Post-translational Modification<br/>Deubiquitination]
end
subgraph Activation
E[Triggers<br/>ATP, ROS, Mitochondrial<br/>DNA, Crystals] --> F[NLRP3 Oligomerization] -->
F --> G[ASC Recruitment] -->
G --> H[Pro-Caspase-1 Recruitment]
end
I[Caspase-1 Auto-cleavage] --> J[Active Caspase-1] -->
J --> K[Pro-IL-1β Cleavage] -->
J --> L[Pro-IL-18 Cleavage] -->
J --> M[Gasdermin D Cleavage] -->
K --> N[IL-1β Release] -->
L --> O[IL-18 Release] -->
M --> P[Pyroptosis<br/>Inflammatory Cell Death] -->
N --> Q[Chronic Neuroinflammation] -->
O --> Q
P --> Q
NLRP3 inflammasome inhibitors are actively being developed:
| Strategy |
Compound |
Status |
Notes |
| NLRP3 inhibitors |
MCC950 |
Preclinical/Phase I |
Direct NLRP3 ATPase inhibition |
|
Dapansutrile (OLT1177) |
Phase II |
β-sulfonyl nitrile compound |
|
Tranilast |
Approved (allergy) |
Repurposed for NLRP3 |
| IL-1β targeting |
Anakinra, Canakinumab |
Approved |
IL-1 receptor antagonist |
| ASC inhibition |
Small molecules |
Research |
Block inflammasome assembly |
| Caspase-1 inhibitors |
VX-765 |
Clinical trials |
Prevent cytokine activation |
NLRP3-related biomarkers under investigation:
- IL-1β in CSF: Marker of inflammasome activation
- ASC specks: Inflammasome activity in extracellular vesicles
- NLRP3 gene variants: Genetic modifiers of disease risk
- NLRP3 is activated in Alzheimer's disease and contributes to pathology - Heneka et al., Nature 2013
- NLRP3 inflammasome in Parkinson's disease - Mao et al., Nat Neurosci 2016
- Microglial NLRP3 inflammasome and Alzheimer's disease - Song et al., Front Immunol 2018
- NLRP3 as therapeutic target in neurodegeneration - Swanson et al., Nat Rev Drug Discov 2019
- Inflammasome inhibition by MCC950 in neurodegenerative models - Coll et al., Science 2021
Nlrp3 (Nlr Family Pyrin Domain Containing 3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Nlrp3 (Nlr Family Pyrin Domain Containing 3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Search PubMed for latest research on this topic.